Brief: Huakang Biomedical Holdings Co Sees Qtrly Loss Attributable Of About Rmb2.8 Mln
04/05/2020 09:56
May 4 (Reuters) - Huakang Biomedical Holdings Co Ltd
8622.HK :
* SEES SIGNIFICANT INCREASE IN QTRLY LOSS ATTRIBUTABLE FROM
ABOUT
RMB148,000 TO ABOUT RMB2.8 MILLION
* EXPECTED RESULT DUE TO SIGNIFICANT DECLINE IN SALES
REVENUE IN
MARKETS IN CHINA DUE TO COVID-19 EPIDEMIC
Source text for Eikon: ID:nHKS4J9pXK
Further company coverage: 8622.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Joyzyme
See all newsChairman
Brief: Huakang Biomedical Trading In Co's Shares Halted
Brief: Huakang Biomedical Says Zhang Shuguang Resigns As Executive Director And Chairman
Brief: Huakang Biomedical Announces Zhang Yujing Appointed As Executive Director
Brief: Huakang Biomedical To Acquire 51% Interest In Hunan Keyue Biotechnology